Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Ritesh Rathore"'
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: Current guidelines recommend discussion of adjuvant chemotherapy (AC) for stage II colon cancer (CC) with high-risk features despite lacking conclusive randomized trial data. We examined AC administration in this population and its effect
Externí odkaz:
https://doaj.org/article/2756a46d8df64ac28e1c984188231855
Autor:
Archana Thakur, Ritesh Rathore, Sri Vidya Kondadasula, Joseph P. Uberti, Voravit Ratanatharathorn, Lawrence G. Lum
Publikováno v:
OncoImmunology, Vol 7, Iss 12 (2018)
This proof-of-concept study investigates the immune effects in metastatic breast cancer (MBC) patients after “vaccination” with activated T cells (ATC) armed with anti-CD3 x anti-HER2 bispecific antibody (HER2 BATs) followed by immune consolidati
Externí odkaz:
https://doaj.org/article/5a1ad7d089db4197bf27bb3d4c55f81b
Publikováno v:
Prostate Cancer, Vol 2015 (2015)
Background. New nontoxic targeted approaches are needed for patients with castrate resistant prostate cancer (CRPC). Our preclinical studies show that activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) kill prostate
Externí odkaz:
https://doaj.org/article/802faa0de7d14820af54808ac6cef89a
Autor:
Ritesh Rathore, Qin Liu, William Colaiace, Abby Maizel, Nicola Kouttab, Don S. Dizon, Robert D. Legare, Francis J. Cummings, Gerald A. Colvin, Zaid Al-Kadhimi, Archana Thakur, Lawrence G. Lum
Purpose: This study reports a phase I immunotherapy trial in 23 women with metastatic breast cancer consisting of eight infusions of anti-CD3 × anti-HER2 bispecific antibody (HER2Bi) armed anti-CD3–activated T cells (ATC) in combination with low-d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8ca9ce28f709af3abf49d8a78331c0
https://doi.org/10.1158/1078-0432.c.6523541.v1
https://doi.org/10.1158/1078-0432.c.6523541.v1
Autor:
Ritesh Rathore, Qin Liu, William Colaiace, Abby Maizel, Nicola Kouttab, Don S. Dizon, Robert D. Legare, Francis J. Cummings, Gerald A. Colvin, Zaid Al-Kadhimi, Archana Thakur, Lawrence G. Lum
Methods and Materials, Supplementary Tables S1-S6. Table S1. Patient characteristics: Prior chemotherapy, ER/PR/HER2 status, aATC dose, disease status, survival and time to progression data. Table S2. Dose Escalation Table S3. Characteristics and Act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00aef2eb7e8f4d5c9ba8132ee2f5fcea
https://doi.org/10.1158/1078-0432.22457237
https://doi.org/10.1158/1078-0432.22457237
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S382-S383
Introduction Autoimmune hemolytic anemias (AIHAs) are a group of disorders with warm-, cold-, or mixed-reactive antibodies against the red blood cell surface. AIHA is a disorder of hyperfunctioning B lymphocytes associated with immune-related disorde
Autor:
Archana Thakur, Lawrence G Lum, Gerald A Colvin, Patrick Dillon Patrick Dillon, Ritesh Rathore Ritesh Rathore
BACKGROUND: Advanced stage breast cancer has unacceptably high recurrence rates. In this study, we report a phase I immunotherapy (IT) trial in women with high risk (>3 positive nodes) breast cancer that seeks to determine safety and maximum tolerate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6983d5e8b6c7b6372724b2a8aaae66e3
https://doi.org/10.21203/rs.2.10980/v1
https://doi.org/10.21203/rs.2.10980/v1
Publikováno v:
Cancer Research. 78:P1-08
Background: The balance in the immune system between immune surveillance and tolerance is known to be associated with the prognosis of breast cancer patients. The aim of this phase I study was to assess the safety of anti-CD3 x anti-HER2Bi bispecific
Publikováno v:
European Journal of Surgical Oncology. 44:148-156
Lymph node involvement (LNI) is an important prognostic factor in colon cancer. But, variations in LNI among different age groups are less known. Adequate lymph node evaluation (LNE) requires assessment of ≥12 nodes. In our previous study, using Su
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S412
Introduction T-cell acute lymphoblastic leukemias (T-ALL) and T-cell lymphoblastic lymphomas (T-LBL) are both lymphoblastic neoplasms involving the blood and bone marrow, respectively. T-LBL typically present with lymphadenopathy and/or a mediastinal